PD-1/PD-L1 inhibitor-based regimens in sarcomatoid renal cell carcinoma: a meta-analysis of randomized controlled trials and single-arm studies
In brief
Immune checkpoint combinations cut progression risk by about half in sarcomatoid kidney cancer
Across randomized trials involving 618 patients, first-line PD-1/PD-L1 combinations made tumors about 2.4 times as likely to respond and lowered the risk of progression or death by about half compared with sunitinib. An overall survival benefit was less robust, so longer-term survival estimates remain uncertain despite the stronger response and progression findings.
- Journal
- Frontiers in immunology (Q1)
- Published
- 3 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Kailin Zheng, Lixiang Zhang, Zhilong Huang, Binhua Ye, Peng Ren, Qi Zhang
- PMID
- 43047712
- DOI
- 10.3389/fimmu.2026.1981596
Why clinicians should know about it
- Picked for Urology (paper of the day, 19 November 2026): Comparative systemic-therapy evidence for sarcomatoid renal cell carcinoma
Abstract
OBJECTIVE: To evaluate the efficacy of PD-1/PD-L1 inhibitor-based regimens in advanced or metastatic renal cell carcinoma with sarcomatoid differentiation (sRCC). METHODS: PubMed, Embase, Web of Science, the Cochrane Library, Scopus, and ClinicalTrials.gov were searched through August 13, 2026. Randomized controlled trials (RCTs) comparing first-line combinations with sunitinib were synthesized using random-effects models with modified Hartung-Knapp inference. Risk ratios (RRs) were pooled for objective response rate (ORR) and complete response (CR), and hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS). Prospective nonrandomized cohorts were summarized separately. Risk of bias and evidence certainty were assessed using RoB 2, MINORS, and GRADE. RESULTS: Fifteen cohorts from 13 parent studies were included: six randomized sarcomatoid subgroups (618 patients) and nine prospective nonrandomized cohorts (150 patients at baseline). Compared with sunitinib, combination therapy improved ORR (RR 2.440, 95% CI 1.802-3.305), CR (RR 4.544, 95% CI 1.769-11.675), PFS (HR 0.480, 95% CI 0.360-0.639), and OS (HR 0.587, 95% CI 0.390-0.884). ORR, CR, and PFS remained statistically significant in all leave-one-out analyses; OS did not after omission of three individual trials. Evidence certainty was moderate for ORR and PFS and low for CR and OS. CONCLUSIONS: First-line PD-1/PD-L1-based combinations improve tumor response and PFS compared with sunitinib in patients with sRCC. The pooled OS benefit is promising but less robust. These findings support the use of the studied combinations while highlighting the need for more precise long-term survival estimates. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261490589.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.